



CathRx Ltd
ABN 23 089 310 421
5 Parkview Drive
Homebush Bay NSW 2127
Australia
Telephone +61 (0)2 9397 5700
Facsimile +61 (0)2 9397 5701
www.cathrx.com

ASX Announcement

John Hunter Hospital joins CathRx's Australian registration trial

SYDNEY 29 April 2009: Cardiac catheter manufacturer CathRx Limited (ASX: CXD) today announced the John Hunter Hospital had joined its Australian clinical trial to gather data for Australian Therapeutic Goods Administration (TGA) approval for its quadrapolar and decapolar diagnostic catheters.

John Hunter Hospital is a leading teaching hospital and major cardiology and cardiac surgery centre. CathRx's Australian approval trial began at Westmead Hospital in Sydney in November 2008.

CathRx Chief Executive Officer Neil Anderson said that while the catheters had already been CE marked and are on sale in Europe, the Australian trial was being conducted to enable CathRx to file for Australian approvals.

The protocol at John Hunter Hospital calls for use of CathRx's diagnostic catheters undergoing electrophysiology procedures that require the use of diagnostic catheters. There will be an equal number of CathRx and control patients. The primary end-point is a confirmation of diagnostic capability.

About CathRx

CathRx is a medical device company which manufactures and sells advanced cardiac catheter systems for the treatment of cardiac arrhythmias. CathRx's proprietary diagnostic and therapeutic catheters are designed to give physicians the tools to successfully treat patients with speed, safety and precision. CathRx's first diagnostic products are now on sale in Europe.

About cardiac arrhythmias

Cardiac arrhythmia describes a group of increasingly common conditions where there is abnormal electrical activity in the heart. The beating of a normal heart is controlled by electrical impulses. When these impulses are uncoordinated the heart fails to function properly. This can result in complications ranging from fatigue to stroke and even death. More than 10 million people worldwide suffer from abnormal heart rhythms. Atrial fibrillation is the most common form of arrhythmia and affects over 5 million people worldwide. Current drug therapies often fail to control the problem and can have side effects. Physicians worldwide are increasingly using cardiac catheters to diagnose and successfully treat arrhythmias.

For further information:

*Neil Anderson
CathRx Chief Executive Officer
Ph: 02 9397 5700*

*Jeannene O'Day
Lyon Group
Ph: 0439 865 256*